Weight-Loss Drug Benefit Spans HFpEF, HFmrEF
(MedPage Today) -- CLEVELAND -- Semaglutide 2.4 mg (Wegovy) improved outcomes across the range of moderately reduced and preserved ejection fraction in heart failure (HFmrEF, HFpEF) related to obesity, a prespecified secondary analysis of the...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news
More News: Cardiology | Eating Disorders & Weight Management | Endocrinology | Heart | Heart Failure | Obesity | Weight Loss